Revance Therapeutics Investor Presentation — April 2018

Document content

REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

REVANCE 2018 INVESTOR DAYA P R I L 1 9 , 2 0 1 82

Forward -Looking Statements / Safe Harbor / Market Data

This presentation contains forward -looking statements, including statements related to:our financial outlook and other financial performance ;theprocess and timing of

anticipated future clinical development ofourproduct candidates ;ourbusiness strategy, goals, plans and prospects ;timing and outcome ofourclinical trials ;ourability to

obtain regulatory approval ;thepotential therapeutic and economic benefits and value ofourproduct candidates and ourtechnologies ;demand forourproduct candidates

and drivers ofdemand ;market size, adoption rate and potential revenue ;growth opportunities and product pipeline ;our ability toleverage our investment inour

development and manufacturing platform ;and ourintellectual property strategy .

Forward -looking statements aresubject torisks and uncertainties that could cause actual results todiffer materially from our expectations .These risks and uncertainties

include, butarenotlimited to:theoutcome, cost and timing ofourproduct development activities and clinical trials ;theuncertain clinical development process, including

therisk that clinical trials may nothave aneffective design ;ourability toobtain and maintain regulatory approval ofourproduct candidates ;ourability toobtain funding

forour operations ;our plans toresearch, develop and commercialize our product candidates ;our ability toachieve market acceptance ofour product candidates ;

unanticipated costs ordelays inresearch, development and commercialization efforts ;the applicability ofclinical study results toactual outcomes ;the size and growth

potential ofthemarkets forourproduct candidates ;ourability tosuccessfully commercialize ourproduct candidates and thetiming ofcommercialization activities ;therate

and degree ofmarket acceptance ofour product candidates ;our ability todevelop sales and marketing capabilities ;the accuracy ofour estimates regarding expenses,

future revenues, capital requirements and needs forfinancing ;and our ability tocontinue obtaining and maintaining intellectual property protection forour product

candidates .These and other risks aredescribed inthe“Risk Factors” section ofourForm 10-Kfiled with theSecurities and Exchange Commission onMarch 2,2018 .

This presentation also includes information about theglobal neuromodulator market, including growth and trends, that isbased onvarious publicly available sources and

onanumber ofassumptions and limitations .The industry data and third -party overview included inthis presentation have been obtained from sources believed tobe